Español
43rd Annual J.P. Morgan Healthcare Conference
Andreas Segerros, CEO at Sylentis, will be representing our team at the conference.
Loading view.
6th RNAi-Based Therapeutics Summit
Sylentis sponsor as Innovation Partner
First General Assembly and Annual Conference of the IPCEI Med4Cure
Ministère de l'Economie, des Finances, de la Souveraineté industrielle et numérique 139 rue de Bercy, Paris, FranceLeveraging RNA-based production processes: European models of innovation (17:00-17:45h) Ana Isabel Jiménez, Managing Director of Sylentis,
ARVO 2025
Salt Lake City, Utah Salt Lake City, UT, United StatesUS Tides 2025
San Diego, USA San Diego, CA, United StatesStand: 212 Assistants: Lola Company and Pablo Lores Lareo
International Oligonucleotide and Peptides Conference 2025
Praga Prague, Czech RepublicAssistant: Pablo Lores Lareo
Farmaforum 2025
Madrid Av. del Partenón, 5, Barajas, Madrid, Spain
Oligonucleotide Therapeutics Society meeting 2025
Budapest Budapest, HungaryAssistants: Lola Company y Pablo Lores Lareo
Tides EU 2025
Basel Basel, SwitzerlandAssistant: Pablo Lores Lareo
IPCEI Health MED4CURE Information Day
Where: Multipurpose Room of CDTI (C/ Cid, 4 - Madrid) Contact: comunicacion@cdti.es
7th RNAi-Based Therapeutics Summit, Boston (USA)
Assistant: Pablo Lores Sylentis will participate as a sponsor More information: Home - 7th RNAi-Based Therapeutics Summit
TIDES ASIA, Tokyo
Further information: TIDES Asia: Oligonucleotide & Peptide Therapeutics Ana Isabel Jiménez and Pablo Lores will be representing Sylentis. Pablo will give two lectures: "Phase-appropriate CMC considerations for next generation oligonucleotides" "Lessons learned building an oligo CMC program for small company: doing more with less"
